German researchers hope to use myeloablative therapy and autologous stem-cell transplantation to treat patients with peripheral T-cell lymphomas.

The team of the researchers, led by investigator Dr. Peter Reimer in Wurzburg University Clinic enrolled 83 PTCL patients. The patients who underwent 4 to 6 cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone.

After autologous stem-cell transplant, 48 of 55 patients had a complete response and 7 had a partial response.

This gave an overall response rate in intention-to-treat analysis of 66%. Mainly because of progressive disease, only 55 of the 83 patients underwent autologous stem-cell transplant. At last follow-up, 23 of the 28 of the patients who did not undergo transplant had died.The estimated 3-year survival rate was 71% in patients who underwent autologous stem-cell transplant, compared with only 11% in patients who did not.

Source: Cure